UK-based Grey Wolf Therapeutics raises €46 million Series B to develop disease-modifying therapies for autoimmune disorders

Published on May 23, 2024

Oxfordshire-based Grey Wolf Therapeutics, a clinical-stage biotechnology company leveraging first-of-its-kind antigen modulation therapies to address the source of immune dysfunction in oncology and autoimmunity, announced the closing of an oversubscribed €46 million Series B financing expansion, bringing the total amount of Series B funds raised to $99 million.  The Series B expansion round was led by ICG’s…

This content is for members only. Visit the site and log in/register to read.

The post UK-based Grey Wolf Therapeutics raises €46 million Series B to develop disease-modifying therapies for autoimmune disorders appeared first on EU-Startups.

Continue reading on website
Other news

EU-Startups Podcast | Episode 69: Shirley Romig, Chief Accelerator Investment Officer at Techstars

May 23, 2024
In this episode, Shirley Romig, Chief Accelerator Investment Officer at Techstars, discusses the future of accelerator programs and the importance of ecosystem development. She highlights the need to tap into talent globally and create partnerships that fuel growth for Techstars’ portfolio companies. Shirley also shares valuable lessons she has learned from scaling companies like Lyft… This conten

Bugcrowd, the crowdsourced white-hat hacker platform, acquires Informer to ramp up its security chops

May 23, 2024
On the heels of raising $102 million earlier this year, Bugcrowd is making good on its promise to use some of that funding to make acquisitions to strengthen its security chops. The company — which crowdsources skills from more than half a million hackers to find and fix security vulnerabilities and other operational loopholes in […]© 2024 TechCrunch. All rights reserved. For personal use only.